Login to Your Account

Other News To Note

Monday, June 6, 2011
• Spherix Inc., of Bethesda, Md., said SPX-106 plus D-tagatose significantly reduced triglycerides and cholesterol in mouse models of dyslipidemia. SPX-106 is a small molecule; D-tagatose is a Phase III diabetes compound originally developed as a reduced-calorie sugar substitute. Shares of Spherix (NASDAQ:SPEXD) gained 64 cents, or 19 percent, to close at $4 on Friday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription